Wijnegem, Belgium, October 12th 2016: Novosanis announced today her participation in the Life Sciences week and its presence at BioJapan. During BioJapan, Novosanis will be present at the Belgian pavilion and will present its VAX-ID™ device platform during the Flanders Investment and Trade Seminar. Novosanis considers Japan as an important market due to its innovative vision towards healthcare and vaccination.
Novosanis’ VAX-ID™, an easy-to-use intradermal injection device that allows not only healthcare workers but also non-medical trained people to inject with an unseen ease of use and accuracy. In case of vaccines, only 10% of the dose is needed for immunization via the skin. This offers the significant benefit of being able to vaccinate more people with the same amount of the vaccine. This might be critical in the case of an outbreak or in upscaling the production of a new vaccine. In early phases of clinical medicinal research, VAX-ID allows de-risking the trial by de-skilling the administrators of the injectables.
“VAX-ID is a true game changer. It’s ease of use and high accuracy offers new possibilities to pharmaceutical companies and institutes active in disease prevention and control.” says Koen Beyers, Chief Technology Officer at Novosanis.